{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-280125","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.468105+00:00","generated_at":"2026-05-16T20:18:28.545633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kodiak Sciences Q3 net loss $61.5M ($1.16/share); cash $72M; Phase 3 trials on track","bullets":["Net loss of $61.5M ($1.16/sh) vs $43.9M ($0.84/sh) in Q3 2024; R&D expenses rose to $50.5M from $31.9M on higher clinical and manufacturing activity.","Cash and equivalents $72.0M as of Sept 30, 2025, down from prior quarter given ongoing Phase 3 spend.","Phase 1b APEX (KSI-101) showed ≥90% of patients in top doses achieved absence of retinal fluid; Phase 3 PEAK/PINNACLE enrolling faster than expected.","Phase 3 DAYBREAK (tarcocimab/KSI-501) in wet AMD completed enrollment of ~690 patients; topline data expected 3Q 2026.","Upcoming catalysts: GLOW2 topline 1Q 2026; KSI 101 Phase 3 topline 4Q 2026/1Q 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-280125","json":"https://secwatch.observer/filing/0001193125-25-280125.json","markdown":"https://secwatch.observer/filing/0001193125-25-280125.md","text":"https://secwatch.observer/filing/0001193125-25-280125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000119312525280125/0001193125-25-280125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000119312525280125/kod-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:18:28.545633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}